enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
11.96
+0.50 (4.32%)
At close: Mar 9, 2026, 4:00 PM EDT
11.83
-0.13 (-1.06%)
After-hours: Mar 9, 2026, 4:10 PM EDT

Company Description

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease.

The company’s lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency.

Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh.

The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories.

The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.

enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

enVVeno Medical Corporation
enVVeno Medical logo
Country United States
Founded 1987
Industry Medical Devices
Sector Healthcare
Employees 37
CEO Robert Berman

Contact Details

Address:
70 Doppler
Irvine, California 92618
United States
Phone 949 261 2900
Website envveno.com

Stock Details

Ticker Symbol NVNO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661053
CUSIP Number 29415J106
ISIN Number US29415J2050
Employer ID 33-0936180
SIC Code 3841

Key Executives

Name Position
Robert A. Berman Chief Executive Officer and Director
Dr. Hamed Alavi Ph.D. Senior Vice President and Chief Technology Officer
Dr. Marc H. Glickman M.D. Senior Vice President and Chief Medical Officer
Jennifer Bright CPA Chief Financial Officer
Sandy Prietto Vice President of Marketing
Andrew Cormack Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 20, 2026 SCHEDULE 13D Filing
Feb 20, 2026 SCHEDULE 13D Filing
Feb 17, 2026 SCHEDULE 13G/A Filing
Feb 10, 2026 SCHEDULE 13G Filing
Feb 10, 2026 SCHEDULE 13G Filing
Feb 4, 2026 8-K Current Report
Jan 20, 2026 8-K Current Report
Dec 12, 2025 8-K Current Report
Dec 2, 2025 DEFR14A Filing
Nov 20, 2025 8-K Current Report